Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Fine particle pollution raises rheumatoid arthritis flare risk and disease activity

7

Aug 2026

Fine particle pollution raises rheumatoid arthritis flare risk and disease activity

Higher ambient PM2.5 exposure was associated with increased rheumatoid arthritis disease activity and a greater likelihood of flares in a four-year South Korean cohort of 1,070 patients. The association appeared stronger with sustained exposure over approximately two weeks or longer, while women and nonsmokers showed more pronounced links between PM2.5 and DAS28-CRP.

Genetic analysis of 1 million people points to FNIP1 as a promising metabolic target

7

Aug 2026

Genetic analysis of 1 million people points to FNIP1 as a promising metabolic target

Mega-scale exome sequencing of 1,032,116 people identified 59 independent genes linked to the TG:HDL ratio, including 44 rare-coding associations not detected in the previous largest analysis. Ultra-rare FNIP1 loss-of-function variants were associated with favorable fat distribution, lower liver fat and glycemia, and around 60% lower odds of a composite cardiometabolic disease outcome.

Severe COVID-19 reactivates dormant viruses and may leave a lasting viral signature

7

Aug 2026

Severe COVID-19 reactivates dormant viruses and may leave a lasting viral signature

A longitudinal study of 1,154 hospitalized COVID-19 patients found widespread reactivation of chronic Herpesviridae and Anelloviridae, with distinct viral patterns linked to disease severity, inflammation, and clinical outcomes. Anelloviridae also persisted during convalescence and were associated with physical deficits in long COVID, although the study did not establish causation.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.